Display Settings:

Format

Send to:

Choose Destination

    FEMS Microbiol Lett. 1990 May;57(1-2):43-7.

    A Staphylococcus aureus plasmid that specifies constitutive macrolide-lincosamide-streptogramin B resistance contains a novel deletion in the ermC attenuator.

    Catchpole I, Dyke KG.

    Department of Biochemistry, University of Oxford, U.K.

    A 2.5 kb plasmid, pA22, isolated from a naturally occurring S. aureus strain confers constitutive MLS-resistance. By restriction enzyme analysis, pA22 is indistinguishable from the S. aureus inducible MLS-resistance conferring plasmid, pT48, apart froma small deletion. DNA sequencing showed that the deletion, is in the leader/attenuator region of the ermC (MLS-resistance) gene and removes some of the complementary repeat regions required by the translational attenuation model in pT48 for inducible ermC expression. The deletion in plasmid pA22 is different from that found in similar 2.5kb constitutive MLS-resistance plasmids in other Gram-positive bacteria. It is suggested that plasmids conferring the constitutive phenotype have evolved from an inducible ancestor on several independent occasions.

    PMID: 2116351 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Erythromycin (ERY-C®, Ery-Tab®, Erythromycin Base Filmtab®, ...)

      Erythromycin is an antibiotic used to treat certain infections caused by bacteria, such as bronchitis; diphtheria; Legionnaires' disease; pertussis (whooping cough); pneumonia; rheumatic fever; venereal disease (VD); and...